Loading clinical trials...
Loading clinical trials...
An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg Eltrombopag in Healthy Subjects and in Subjects With Mild, Moderate, or Severe Renal Impairment
Conditions
Interventions
eltrombopag
Locations
2
United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Saint Paul, Minnesota, United States
Start Date
September 28, 2006
Primary Completion Date
January 3, 2008
Completion Date
January 3, 2008
Last Updated
November 13, 2017
NCT01072162
NCT01064336
NCT01098487
NCT00424177
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions